Pharmacogenetic components detection of Polygonati Rhizoma Coll. et Hemsl in the liver mitochondria of metabolic associated fatty liver disease by Semi-Pre-HPLC combined with HPLC-MS of two-dimensional chromatographic analysis system
SHI Tingting1* LI Yanjuan2* YANG Ai2 WANG Tao2 SONG Chengzhu2 XI Jianjun1 JIANG Xiaojie1 YANG Xingxin2▲
1.Manufacturing Laboratory, Affilliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Zhejiang Province, Hangzhou 310000, China; 2.College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China
Abstract：Objective To detect the pharmacogenetic components of Polygonati Rhizoma Coll. et Hemsl in liver mitochondria of metabolic associated fatty liver disease (MAFLD). Methods Twenty-four 6-week-old male SD rats were divided into normal group, model group, and Polygonati Rhizoma Coll. et Hemsl water extract group by random number table method, with eight rats in each group. The normal group was fed ordinary diet, and the other groups were fed with high fat diet. At the same time, the Polygonati Rhizoma Coll. et Hemsl water extract group was intragastric with Polygonati Rhizoma Coll. et Hemsl water extract at 8 g/(kg·d), and the normal group and model group were given with normal saline at the same volume for 14 weeks. One hour after the last administration, mitochondria were isolated from liver tissues of rats in each group, and the pharmacogenetic components of liver mitochondria of each group were analyzed by Semi-Pre-HPLC combined with HPLC-MS of two-dimensional chromatography analysis system. Results A total of ten pharmacogenetic components were detected in the liver mitochondria of MAFLD rats. Seven of them, diosgenin, dioscin, Smilax saponin, Pratioside D1, isoglycyrrhizin, β-sitosterol, and ivy saponin had been reported to regulate lipid metabolism. Conclusion A total of ten pharmacogenetic components detected may be the main active substances of polygonatum yunnanensis in regulating mitochondria to alleviate MAFLD.
史婷婷1* 李艳娟2* 杨艾2 王涛2 宋成竹2 席建军1 姜晓杰1 杨兴鑫2▲. Semi-Pre-HPLC与HPLC-MS联用的二维色谱分析系统对代谢相关脂肪性肝病肝线粒体中滇黄精药源成分的检测[J]. 中国医药导报, 2023, 20(13): 18-22.
SHI Tingting1* LI Yanjuan2* YANG Ai2 WANG Tao2 SONG Chengzhu2 XI Jianjun1 JIANG Xiaojie1 YANG Xingxin2▲. Pharmacogenetic components detection of Polygonati Rhizoma Coll. et Hemsl in the liver mitochondria of metabolic associated fatty liver disease by Semi-Pre-HPLC combined with HPLC-MS of two-dimensional chromatographic analysis system. 中国医药导报, 2023, 20(13): 18-22.
[1] Eslam M，Sanyal AJ，George J，et al. MAFLD：A consensus-driven proposed nomenclature for metabolic associated fatty liver disease [J]. Gastroenterology，2020，158（7）：1999- 2014.e1.
[2] Eslam M，Newsome PN，Sarin SK，et al. A new definition for metabolic dysfunction-associated fatty liver disease：An international expert consensus statement [J]. J Hepatol，2020， 73（1）：202-209.
[3] National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association，Fatty Liver Expert Committee，Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease：a 2018 update [J]. Zhonghua Gan Zang Bing Za Zhi，2018，26（3）：195-203.
[4] 国家药典委员会.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2020.
[5] Xie W，Du L. Diabetes is an inflammatory disease：evidence from traditional Chinese medicines [J]. Diabetes Obes Metab，2011，13（4）：289-301.
[6] Yuan HJ，Lin SY，Zhang GJ，et al. New thoughts on material basis and mechanism of Yin-tonifying traditional Chinese medicine in treatment of diabetes mellitus and its complications [J]. Zhongguo Zhong Yao Za Zhi，2020，45（3）：531-538.
[7] Gu X，Zhu LY，Xu ZY，et al. Astragaloside Ⅳ and saponins of rhizoma polygonati cure cyclophosphamide-induced myelosuppression in lung adenocarcinoma via down-regulating miR-142-3p [J]. Front Oncol，2021，11：630921.
[8] 金正强，尚丙鹏，张公信，等.天麻、滇黄精和玛咖三种云南药材及种植土壤重金属安全评价[J].中国现代中药，2022，24（8）：1525-1530.
[9] 卫钰成，杨敏敏，施琳，等.滇黄精水提物联合间歇性禁食通过调节肠道菌群改善高脂饮食诱导的小鼠肥胖及肝损伤[J].食品与发酵工业，2022，48（13）：91-102.
[10] 杨兴鑫，穆健康，顾雯，等.滇黄精资源的开发应用进展及前景分析[J].生物资源，2019，41（2）：138-142.
[11] Yang XX，Wang X，Shi TT，et al. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease：The alleviating effect and its mechanism of Polygonatum kingianum [J]. Biomed Pharmacother，2019，117：109083.
[12] 杨兴鑫，王曦，董金材，等.滇黄精对非酒精性脂肪肝大鼠的保护作用及机制研究[J].中国药学杂志，2018，53（12）：975-981.
[13] Jahn D，Kircher S，Hermanns HM，et al. Animal models of NAFLD from a hepatologist’s point of view [J]. Biochim Biophys Acta Mol Basis Dis，2019，1865（5）：943-953.
[14] 李洁，王喻淇，梅晓丹，等.固相萃取结合UHPLC-LTQ-Orbitrap MS分析黄精发酵前后的化学成分[J].中草药，2019，50（13）：3029-3036，3043.
[15] Arya P，Kumar P. Diosgenin a steroidal compound：An emerging way to cancer management [J]. J Food Biochem，2021，45（12）：e14005.
[16] Hashidume T，Sasaki K，Hirata J，et al. Effects of Sanyaku and Its Constituent Diosgenin on the Fasted and Postprandial Hypertriacylglycerolemia in High-Fat-Diet-Fed KK-Ay Mice [J]. J Agric Food Chem，2018，66（38）：9968-9975.
[17] 张玲，冷锦红.薯蓣皂苷元对代谢系统疾病治疗作用及机制研究[J]. 辽宁中医药大学学报，2019，21（6）：161-165.
[18] Cheng S，Liang S，Liu Q，et al. Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways [J]. Int J Mol Med，2018，41（2）：1089-1095.
[19] Li H，Yu L，Zhao C. Dioscin attenuates high-fat diet-induced insulin resistance of adipose tissue through the IRS-1/ PI3K/Akt signaling pathway [J]. Mol Med Rep，2019， 19（2）：1230-1237.
[20] 江文青，李加梅，王韫智，等.异菝葜皂苷元对 H2O2氧化损伤SH-SY5Y 细胞的保护作用及其分子机制[J].上海交通大学学报，2015，35（5）：631-635.
[21] 张小燕.菝葜抗炎有效部位群的成分分析及其体内代谢研究[D].武汉：湖北中医药大学，2016.
[22] 许方舟，张士凯，马航宇，等.黄精皂苷的研究进展[J].饮料工业，2022，25（2）：71-80.
[23] Na AY，Yang EJ，Jeon JM，et al. Protective effect of isoliquiritigenin against ethanol-induced hepatic steatosis by regulating the SIRT1-AMPK pathway [J]. Toxicol Res，2018，34（1）：23-29.
[24] 魏海霞，孔伟，巩萍，等.异甘草素的药效学研究进展[J].药物生物技术，2019，26（5）：467-470.
[25] 张雪茹.β-谷甾醇自微乳和亚油酸β-谷甾醇酯的降脂效应研究[D].合肥：合肥工业大学，2020.
[26] 刘佳慰，李万泉，邹美南.常春藤皂苷元体外降脂活性研究[J].湖北中医杂志，2019，41（2）：3-6.
[27] 殷杰，魏敏平，姚卫蓉.无患子皂苷及常春藤皂苷元生物活性的研究进展[J].林产化学与工业，2021，41（5）：126-134.
京公网安备 11010502046598号